Good morning. And welcome to the IDEXX Laboratories First Quarter 2020 Earnings Conference Call. As a reminder, today’s conference is being recorded. Participating in the call this morning are Jay Mazelsky, President and Chief Executive Officer; Brian McKeon, Chief Financial Officer; and John Ravis, Senior Director, Investor Relations. IDEXX would like to preface the discussion today with a caution regarding forward-looking statements. Listeners are reminded that our discussion during the call will include forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those discussed today. Additional information regarding these risks and uncertainties is available under the forward-looking statements notice in our press release issued this morning, as well as in our periodic filings with the Securities and Exchange Commission, which can be obtained from the SEC or by visiting the Investor Relations section of our website, idexx.com. During this call, we will be discussing certain financial measures not prepared in accordance with Generally Accepted Accounting Principles or GAAP. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP measures is provided in our earnings release, which may also be found by visiting the Investor Relations section of our website. In reviewing our first quarter 2020 results, please note all references to growth, organic growth, constant currency growth, and comparable constant currency growth refer to growth compared to the equivalent period in 2019, unless otherwise noted. To allow broad participation in the Q&A, we ask that each participant limit his or her questions to one with one follow-up if necessary. We appreciate you may have additional questions. So, please feel free to get back into the queue and if time permits, we will take your additional questions. I would now like to turn the call over to Jay Mazelsky.

Thanks, and good morning, everyone. Welcome to the call. Today, we are pleased to report strong Q1 results, despite late quarter impacts from the COVID-19 crisis. As we will discuss, the COVID-19 pandemic is impacting our care customers in unusual ways, given broad-based social distancing efforts, which are changing the ways veterinarians are prioritizing and providing care. We are working through these near-term dynamics, ensuring that we are fully supporting these essential health services in a way that prioritizes our customers’ needs. We are doing this while we continue to advance our business strategy. Today, Brian will review our Q1 results and provide an update on current trends that we are seeing in our markets and our business. He will also describe the steps that were taken to mitigate near-term impacts and position ourselves for a strong and sustained recovery in the highly attractive pet health care market. I will then talk more about how we are seeing trends evolve in the market and how we are managing our business for the near-term and the long-term in this context. Now, I will turn the call over to Brian.

Thanks, Jay, and good morning, everyone. We will be using a somewhat different format for today’s financial review. I will begin with an overview of our first quarter financial results, which resulted in solid revenue and profit gains despite late quarter impacts related to the COVID-19 pandemic. We will then spend time discussing the near-term dynamics that we are seeing in the companion animal health care market, including evolving impacts from COVID-19 containment approaches on clinical visits and diagnostic testing levels. We will review how we plan to manage in this environment and highlight the steps we have taken to mitigate near-term P&L impacts and strengthen our balance sheet and flexibility to position our business for a strong recovery. While we are optimistic about the ability of the pet health care market and IDEXX’s business in particular to rebound strongly from near-term COVID-19 effects, we are withdrawing our full-year financial guidance as we work through these dynamics. As such, we won’t be providing an update on that front today. Let’s start with an overview of our Q1 results. IDEXX delivered 9% organic revenue growth in the first quarter, supported by 10% growth in CAG Diagnostics recurring revenues, reflecting double-digit gains across both U.S. and international markets, as well as solid gains in our Water and LPD businesses. Overall, organic revenue growth benefited by less than 1% from accelerated stocking orders in our Water and LPD businesses related to the COVID-19 pandemic. Through early March, global CAG Diagnostics recurring revenue gains were trending very strongly, above the high end of our full-year goals for 11% to 12% organic growth. We were also tracking towards an excellent instrument placement quarter driven by continued momentum in new and competitive catalyst placements globally. These gains were against a backdrop of improved market trends, reflected in 4% same-store growth in U.S. clinical visits through this period. As social distancing policies advanced more broadly in Europe and the U.S. through March and as vet clinics adapted to prioritize health care procedures to align with industry and government guidelines, we saw significant declines in clinical visit activity and restriction on access to vet clinics, which moderated our Q1 revenue gains. Despite these impacts, our business momentum enabled strong overall Q1 organic revenue growth across our modalities. Global Reference Lab revenues increased 9%, reflecting 8% organic gains and approximately 2% growth benefit from acquisitions, offset by a 1% FX headwind. Through early March, Global Lab organic growth rates were excellent, driven by continued mid-teen organic revenue growth in the U.S. and high single-digit gains in international markets. For Q1 overall, late quarter social distancing impacts constrained U.S. lab organic growth to high single-digit rates and international lab organic growth to the low-to-mid single-digit range. IDEXX VetLab consumable revenues increased 14% on an organic basis, despite late quarter COVID-19 impacts, reflecting low double-digit gains in the U.S. and mid-teen growth in international markets. Our consumable revenue growth results through early March were also very strong benefiting from an expanded premium instrument installed base, sustained high levels of customer retention, and continued gains in testing utilization. The quality of CAG instrument placements remained high in Q1 reflected in 238 catalysts placements at new and competitive accounts in North America and 698 new and competitive placements in international markets. We also benefited from 273 second catalyst placements driven by momentum with North American customers. These gains and sustained high customer retention levels supported a 17% year-on-year growth in our global catalyst install base. We also achieved 760 premium hematology placements and 408 SediVue placements bringing our global SediVue install base to over 9300 instruments, up 32% year-on-year. Restriction on access to vet clinics in late March led to deferrals of quarter-end in placements, however, which contributed to year-on-year instrument organic revenue declines of 16% overall in the first quarter. Rapid Assay revenues increased 6% organically in Q1 despite late quarter COVID-19 impacts supported by solid volume growth in SNAP 4Dx Plus first-generation and specialty products and moderate net price gains. First quarter results reflected normal promotional and customer stocking activity, which supported volume gains ahead of the peak testing season. In other areas of our CAG business, our veterinary software and diagnostic imaging revenues achieved 11% organic growth, supported by continued strong gains in recurring service revenues, as well as sustained solid sales of new Cornerstone and digital imaging systems, and strong growth in our Neo and SmartFlow cloud-based software offerings. Overall gains were also constrained by COVID-19 related impacts on vet clinics late in Q1, which led to a deferral of new software and digital system installations. Turning to our other business segments, we saw a strong performance in our Water and LPD businesses in Q1. Water revenues increased 15% organically, including an estimated $2 million or 8% growth rate benefit from accelerated stocking orders. Overall, our Water business demand has remained solid globally as drinking water testing remains an essential service and priority for local governments and utilities. Livestock, poultry, and dairy revenue increased 12% organically in Q1, including approximately $3 million or 9% of growth rate benefit from accelerated stocking orders. LPD results benefited from demand for diagnostic testing programs for African swine fever and improvement in core swine testing volumes in China. We are also seeing continued solid growth for poultry testing. Overall LPD gains were constrained in Q1 by lower herd health screening levels compared to strong prior year results impacted by the rebuilding of herd populations in key Asia-Pacific markets, which is reducing export supply. Livestock diagnostics are also considered essential services supporting continued demand for LPD products. Turning to the P&L, profit results were strong in Q1 benefiting from solid revenue gains and controlled operating expense growth. Operating profit in Q1 increased 8% as reported and 11% on a constant currency basis, driven by solid operating profit growth across our CAG Water and LPD segments. Operating margins increased approximately 30 basis points on a constant currency basis, reflecting operating expense leverage on strong revenue gains. Gross profit increased 8% as reported or 10% on a constant currency basis in Q1. Gross margins were relatively flat year-on-year on a constant currency basis, as benefits from strong consumable and Water growth and continued moderate net price gains were offset by relatively lower margins in our Reference Lab business, reflecting late quarter pressure on lab revenues related to COVID-19 impacts, lab capacity investments advanced in 2019 and effects from the integration of the Marshfield acquisition. Operating expenses in Q1 increased 9% as reported and on a constant currency basis. Operating expense increases were driven by cost related to the expansion of our Global CAG commercial capability advanced in 2019 and growth in corporate, general, and administrative costs, including the onboarding of our Westbrook Maine headquarters expansion. During the quarter, we benefited from early efforts to prioritize investments and controlled discretionary spending to mitigate emerging COVID-19 impacts. EPS in Q1 was a $1.29 per share including tax benefits of $6.6 million or $0.08 per share related to share-based compensation activity. On a comparable constant currency basis, EPS increased 13%. Overall, we are pleased to have delivered strong financial results in Q1, despite late quarter headwinds related to the COVID-19 pandemic. Let’s now spend some time discussing how social distancing policies and associated restrictions on business activity are impacting veterinary clinic visits and our CAG business in the near-term. Clinical visits have been impacted significantly by the COVID-19 pandemic through the implementation of social distancing protocols, as well as the industry guidelines for the prioritization of sick patient and emergency procedures at vet clinics. These dynamics can be seen in U.S. vet clinic tracking data, which is shown in the earnings snapshot on our IR website. We have added weekly tracking data for 2020 clinical visits extended through the week ended April 24th in the snapshot, as well as detail for wellness and non-wellness visits. As shown in this data, for the first quarter through early March on a same-store basis, clinical visits were up approximately 4% in the U.S., a solid improvement from 2019 trends. As social distancing procedures expanded in March, we saw a sharp correction in these trends, with same-store U.S. clinical visits declining approximately 25% for the weeks ended March 27th through April 10th with 15% to 20% year-on-year declines in sick patient visits and 35% to 40% declines in wellness visits during this period. We saw similar dynamics in European markets with more significant declines in severely impacted regions like Italy and Spain, as well as markets which implemented more restrictive stay-at-home policies like the U.K. In addition to this clinical visit data, we have been monitoring rolling weekly averages for chemistry slide run volumes and Rapid Assay runs through our global smart service connectivity, as well as rolling weekly trends for accession volumes in our Reference Labs. In the late March through the early to mid-April period, we saw meaningful pressure on diagnostic testing levels associated with the restrictions on veterinary clinical activity. These initial impacts were relatively more significant in our Reference Lab and Rapid Assay businesses with average weekly volume declines of approximately 30% in the U.S. and approximately 35% in Europe during this period, with more moderate impacts in Asia-Pacific markets. Testing volume in these modalities were impacted in part by the de-emphasis of wellness testing at clinics as part of the pandemic response, consistent with industry guidelines. VetLab in clinic chemistry run volumes to relatively less effective during this initial period reflected an approximately 20% run declines in the U.S. and 25% declines in Europe. These metrics reflected lower test utilization levels, as well as moderate reduction in the number of clinics actively operating during this initial high-impact period. Over the last two weeks, we have seen significant improvement in clinical visit and diagnostic testing trends. These changes reinforced the high resilience of demand for companion animal health care and may indicate that we work through the bottom of near-term COVID-19 effects on veterinary care. For the most recent week ended April 24th, overall U.S. clinical visits declines have moderated to 15% year-on-year with only 9% year-on-year declines for sick patient visits and 24% year-on-year declines for wellness visits, with steady improvement across U.S. regions week by week. We are seeing similar indications of improvement in European markets and in Asian regions which were impacted at an earlier stage by the pandemic. In terms of our business, we continue to see pressure on diagnostic testing levels. However, these impacts have improved meaningfully. In the U.S. and Europe on a rolling seven-day basis, IDEXX VetLab chemistry run declines have now moderated to approximately 5% year-on-year and Reference Lab accession volume declines have moderated to 10% to 15% overall, with continued steady weekly improvement across regions. Chemistry slide runs in leading-edge markets like China have actually returned to double-digit growth over the last eight weeks following the significant initial impacts on clinical activity. These changes vary by region may change depending on region-specific dynamics related to the COVID-19 pandemic, but overall recent trends have been very encouraging. As we track data on COVID-19 related impacts over time, some insights are emerging. One insight is that most veterinary practices have sustained operations as an essential service through this initial high social distancing period positioning the market for a strong recovery. In the U.S., our tracking of the number of customers doing chemistry runs only declined to about 90% to 95% of prior year levels during the peak pressure period in early April and has now returned to prior levels over the last two weeks. Active customer tracking metrics have also rebounded strongly in Europe where we saw more meaningful reduction in active clinic levels earlier in the COVID-19 expansion in lockdown regions like Italy and Spain. We are seeing the same structural market strength in Asia-Pacific regions as well. The second insight is that the effects on diagnostic testing levels appear to be heavily influenced by the stage of development of COVID-19 case management and the associated stage of stay-at-home and social distancing procedures. There is a significant variation in the level of decline in diagnostic testing volumes by region. Regions with higher relative COVID-19 cases and expanded lockdown policies have experienced much more significant clinical visit and diagnostic testing volume declines. As an example, clinical visits in the Northeast U.S. declined approximately 35% in late March to mid-April, while Southern U.S. regions decline approximately 20% during this period with more recent data from Southern U.S. region showing year-on-year declines of less than 10% overall. Internationally, near-term pressure and lab accession volumes in regions like Germany have been much more moderate compared to markets with extended lockdown conditions like the U.K. and Canada. In Asia-Pacific markets, we are also seeing moderated impact in regions that are farther along in terms of managing pandemic effects, including recent solid growth in the IDEXX Lab chemistry runs in markets like Australia, which has less restrictive social distancing controls. This is a dynamic we will continue to monitor and which is challenging to predict. Overall, it does appear that as regions move past peak levels for COVID-19 cases and adjust stay-at-home and social distancing procedures, near-term pressures on clinical visit activity and related diagnostic testing lessen significantly. While we remain very optimistic about the health care market and IDEXX’s ongoing growth opportunity reinforced by recent encouraging trends, COVID-19 pandemic effects will pressure our near-term revenue results. Given the high gross margin of our IDEXX VetLab and Rapid Assay products and our intent to sustain our Reference Lab operating and service capability to position ourselves for recovery in demand as market restrictions are lifted, we anticipate a high level of gross margin flow-through impact from near-term CAG Diagnostic recurring revenue pressures. To mitigate these impacts, we have advanced prudent steps to reduce planned operating expenses by approximately $25 million on a quarterly basis compared to the original plan levels. This includes temporary reductions in salaries of 30% for the CEO, 20% for officers and senior executives, and 10% for the majority of other salaried employees, which we plan to cease over time as business conditions improve, as well as temporary freezing of 401(k) matching contributions and suspension of cash compensation for IDEXX’s Board of Directors. Our balance sheet is in a very strong position and we have taken additional steps to strengthen our liquidity and flexibility to advance our business strategy and market position during this period. We ended Q1 with leverage ratios of 1.70 times gross and 1.59 times net of cash, with $81 million in cash and $360 million in capacity available on our then $850 million revolving credit facility. In April we increased committed financing availability by $350 million by expanding our credit facility to $1 billion under new three-year agreement and by issuing $200 million of 10-year 2.5% fixed rate notes. In the current environment where prior to funding of our business operations and have suspended our stock repurchase program. Overall, we are very pleased with the strong momentum demonstrated in our business in Q1. We have a great business model and we are confident we can manage effectively through near-term impacts from COVID-19 in our CAG business, while positioning ourselves for a strong recovery in the highly attractive and resilient companion animal health care.

That concludes our financial review. I will now turn the call over to Jay for his comments. Thank you, Brian, for your comments on Q1 financial performance. We are pleased with our solid Q1 results despite late quarter impacts from the COVID-19 crisis. We went into the year with strong momentum and through early March, global CAG Diagnostics recurring revenue gains were trending above the high end of our full-year goals for 11% to 12% organic growth. We were still able to deliver 10 percentage points CAG Diagnostics recurring organic growth in Q1, supported by double-digit growth in the U.S. and international in spite of impacts from China in the early part of the quarter, from Italy in early March, and then for much of Europe and North America shortly thereafter. Instrument placements were excellent in Q1 resulting in sustained year over year levels of Catalyst EBI. Our catalyst installed base grew 10% in North America and 25% internationally with the overall premium instrument installed base increasing 15%. We developed a new remote installation process for instruments, which also supported placements in impacted regions. The IDEXX Preventive Care program enrollments also achieved record levels with approximately 400 new enrollees and more than 4,200 cumulative enrollments since program inception. This was accomplished despite late quarter impacts from COVID-19. Customers continue to embrace the IDEXX Preventive Care turnkey solution in record numbers and increasingly view it as a foundational element of their care offering. Though we expect in some cases for implementation to take a bit longer due to COVID-19 impacts, the IDEXX Preventive Care program will be a key element of what we and our customers see as a recover-together plan for North America. Our product innovations announced at VMX were launched on schedule and were enthusiastically greeted by customers. Our digital cytology placements starting in early March were primarily sold to larger IDEXX customers via our IDEXX 360 program. Customers are enthusiastic about our test promise, results, and expert interpretation in under two hours, 24 hours a day, seven days a week, 365 days a year. Catalyst Bile Acids with Reference Lab quality performance was also launched in the quarter. We are pleased with the adoption to date with over 340 customers. SediVue Neural Network 5.0 updates began rolling out in March and advanced bacteria detection kits starting to ship in April. Our innovation highlights also included the announcement in Q1 that we would begin monitoring clinically symptomatic pets for COVID-19 infection. We then announced in April that we would offer this test commercially throughout the world based on a small number of confirmed COVID-19 cases in cats, experiments that demonstrated the susceptibility of cats and ferrets, and veterinarian demands for testing option. We expect this veterinary test to not have an impact on human COVID-19 testing or test availability. Additionally, the company’s human health business OPTI Medical Systems is advancing support of human COVID-19 testing with a validated PCR test kit enabled by IDEXX’s expertise in livestock PCR, test development, and manufacturing. It is intended for limited initial distribution to existing customers, including labs serving animal production needs that have been repurposed for human COVID-19 testing. Moving to software, we saw excellent ongoing momentum in our software business, which I will speak to later, with over 10% growth in PIMS placements in North America, record orders for SmartFlow and with now over 4,800 customers on Web PACS subscriptions. Moving to a quick update on our European core lab located in Kornwestheim, Germany. We have begun testing and it remains on track to transition by the end of Q2. We are excited by the world-class capabilities in this facility, which is 50% larger than our next biggest lab will bring to our European Reference Lab customers. Our team has done an amazing job to stay on track despite the pandemic. Finally, our Water and Livestock, Poultry, and Dairy businesses both performed solidly in Q1. Demand for livestock diagnostics testing is also considered essential and we are seeing sustained solid demand in our LPD business. Brian highlighted some of the dynamics we are seeing in the market and our testing volumes from COVID-19. Next I will discuss how we are managing in this environment, helping our customers, and positioning ourselves for the future. Let’s start with how the COVID-19 pandemic is impacting the IDEXX workplace and employee safety. Approximately 60% of our employees are now working from home. We have invested heavily in telephony and IT infrastructure over many years, so that we were able to transition a majority of our employees home without missing a beat. Still, other jobs require employees to be on site like those in manufacturing, distribution, and the Reference Labs. We have instituted practices at these locations to minimize risk like staggered shifts or frequent and deeper cleaning and local social distancing procedures. Our teams continue to stay highly engaged and productive. Not only have we launched products on schedule, like the previously mentioned digital cytology service, Catalyst Bile Acids, and advanced bacteria detection for SediVue, but we continue to advance our product pipeline, as our teams are adapting to the new circumstances in highly creative ways. Moving to how veterinary practices are being impacted. They are experiencing similar challenges as other businesses based on client visits. The good news is that veterinary practice has been designated as essential businesses throughout the U.S. and in almost all countries. The vast majority are open and operating, and we are still performing essential services for their clients caring for sick and injured pets in need of attention. Demand for other services, including wellness visits and elective activities have slowed due to government policies and guidance from veterinary organizations designed to control COVID-19 spread. Though our veterinary customers are consequently seeing fewer patient visits at this point, volumes impacted are in line with the aggressiveness of social distancing procedures. Many services are only deferred, and we believe we will return relatively quickly as in past downturns once the recovery begins. We believe the bond between people and their companion animal family members is as strong as ever. As Brian noted, we have seen dampened demand relatively more in our Reference Lab business versus testing in the clinic. This is related in part to fewer preventive care visits versus those involving a sick patient. Further, practices, like all businesses, are also concerned with workplace and employee safety. They have instituted practices like curbside drop off and pickup, remote check-in and bill pay, along with the creation of modified shifts for veterinary staff to ensure care team well-being and continuity for clients. Our field service organization has played an important role helping customers make these required adjustments to their practice workflow in this new COVID-19 environment. IDEXX sales professionals have also adjusted well to this dynamic, continuing to generate demand for our products and services. Virtual visits than our standard can be highly sophisticated. Our sales professionals are using tools like WebEx for demos and DocuSign to bring pipeline deals across the line. We also continue to visit practices when requested by a customer and with an appointment, abiding by necessary safety procedures. Our in-person availability has been welcomed by customers and in April constituted about 25% of total U.S. visits. Veterinarians look to business partners at all times, but even more so now to have sufficient product supply on hand and be able to supply services like Reference Lab testing in an uninterrupted manner. They want to focus on their businesses and now that their partners can handle theirs. IDEXX has performed exceptionally well in this regard and we have high confidence that we can continue to do so in the future. Our manufacturing operations are largely based in the U.S. and we have excellent visibility to secondary suppliers for key components and products that we do not directly manufacture. Our Reference Lab performance has been especially noteworthy in light of the disrupted flight schedules, challenging logistics, and more complex workplace procedures to keep lab employees safe. With over 80 labs worldwide, not unexpectedly, there have been a handful of instances where we needed to temporarily shut a facility for a short time due to an employee being or suspected of being infectious. Because of our network lab capability across regions and geographies, we were able to seamlessly toggle to an alternative lab without service disruption or deterioration. These capabilities are unique in the industry and only possible because we have made significant investments over a very long period of time in lab density, common lab information management systems, and courier route and logistics capability. We also deployed a global lab digital cytology service in the middle of all of this, another example of global agility and advantage. Our commercial execution also continues to be noteworthy. Our expansion in the U.S. was completed going into Q1 and the team seamlessly settled into the new territories and account assignments. Our account managers continue to call on customers with similar frequency, but now the majority of visits are virtual. Our European commercial team continues to mature in the VDC model and is also performing at a high level. We entered into the year with record customer loyalty across modalities and all actions taken to date have been taken with the long-term view to continue to earn this loyalty for years to come. IDEXX veterinary software and services are also playing an important customer enabling role in this pandemic. Right now, customers are being forced to rethink how they deliver patient care, and IDEXX’s software solutions both new and existing to help them adapt. The IDEXX telehealth offering includes multiple third-party telehealth integrations into our global PIMS offering, 90-day free secure remote access for our Cornerstone customers, the ability to use SmartFlow through an iPad from their parking lot for curbside check-in, and contactless payment processing integrated with their IDEXX PIMS. These capabilities enable customers to deliver remote care, as well as continue to see patients in their practices while abiding by social distancing guidelines. We also believe that in the medium term, telehealth can expand demand for diagnostics, the deeper pet owner client connections enabled by real-time, convenient communications that millennial pet owners expect and pet owners of all ages appreciate. Further, telehealth has the potential to expand patient access, especially for cats, who comprise only approximately 20% of practice visits today. Next, I will share a snapshot view of the health of the business. There are broad macroeconomic uncertainties as to the depth and length of the impacts from COVID-19. Consequently, our focus has been on what we can control in our plans for recovery. We took quick and deliberate action to prudently control costs, while leaving us well-positioned for future growth. These include a temporary salary reduction, reductions in our essential business and capital expenses and a cessation of stock buybacks. Our intent is to seize those reductions that are temporary like salary reductions as conditions improve. Critically, these actions were taken in ways that allow us to preserve the considerable strategic advantages, talent, and organizational engagement we have as a company. Our financial strength has allowed us to support veterinarians at a time when they need us most, and I believe they will reward our approach with their business long into the future. We have taken practical actions which extend payment terms for customers who need it, as well as to provide near term flexibility for minimum commitments, while maintaining these long-term diagnostic partnership agreements with customers. Customers have given us and will continue to give us as much testing volume as possible. Our focus is therefore to support the health of their practices and allow them to focus on delivering excellent medical care in a challenging environment and when the time comes, support them as they quickly rebuild client traffic. We participate in great markets. Nothing has changed in this regard due to COVID-19 social distancing practices that have temporarily limited veterinary visits. If anything, pet owners have become even more attached to their companions as they spend even more time with them at home. Pet adoptions and fostering are at an all-time high and breeders in many instances report waiting lists of 12 or more months. And most importantly, pets still need to go to the veterinarian, and most pet owners do not consider these visits to be discretionary. Diagnostics will continue to play a central and growing role in the care of the patient, as well as practice health. Many practices have seen accelerating impact from e-tailers' gains in online sales of food and medicine. This is business that is not likely to come back at the same levels. Veterinarians will continue to look for practice categories like diagnostics that are medically necessary, drive the care envelope and almost always best done in the practice. Our belief is that as a result of pent-up demand from COVID-19, which has constrained care that is desired and needed, though perhaps not time-critical, veterinary practices might experience a stronger V-shaped recovery than the vast majority of other market segments. We see some early evidence of this in select markets like China and Australia and regions within the U.S. where these markets have begun to relax strict shelter-at-home policies. Practices will be in good shape to meaningfully take up where they left off, though they have reduced hours and furloughed employees in some instances, we believe that there isn’t structural damage to the industry or the balance sheet of practice owners. As practices rebuild client traffic with a focus on wellness care, we will be there with our strategic advantages fully impacted. We are using this time wisely, continuing to advance our product pipeline, strengthen relationships and provide exceptional day-to-day service. Unique capabilities that we bring are now even more widely appreciated and keep in mind that this is a highly resilient business with a history of outperforming in economic recovery periods. While these are difficult times, they are an important reminder of our company purpose and that what we do makes a big difference in the lives of pets, people, and livestock. I would like to express my deep appreciation and thanks to the team for their extraordinary support during this period. Now, we will take questions.

Our first question will be from Michael Ryskin with Bank of America. Please go ahead.

Thanks for taking the questions guys. I want to talk about some of the stuff you just touched on Jay, the cost cuts and the salary reductions you implemented earlier in the quarter. Can you talk us through the rationale for that move? It seems like it happened a little bit sooner and was more significant than initially expected. You talked about the V-shaped recovery and the sharp rebound and yet those are some of the meaningful cuts. Is there any concern that you could see increased employee turnover potentially to some of your competitors as a result of this and what criteria are you using to determine when you are with some of these measures, given the improvements you have noted and some end market.

Sure. I'll discuss some of the overarching thoughts and philosophy behind this, and then Brian might elaborate on the specifics. We have a strong business and organization. Our approach to shifts is centered around emerging from this period robustly alongside the market. Pet owners deeply care for their pets and believe that veterinary visits and testing are essential. Veterinarians also recognize that testing is crucial for identifying diseases. Therefore, we aim to maintain our strategic advantages built over decades. For instance, our Reference Lab comprises over 80 labs with superior information management systems and exceptional service levels, even on weekends. We aim to preserve this capability and continue executing our product roadmap, ensuring high engagement within the organization. It's vital that we deliver exceptional service, provide adequate supply when customers need it, and maintain fully staffed customer-facing teams to serve our clients effectively. We approached this situation prudently, fostering engagement and ensuring a positive organizational response. As we move forward, we seek to keep all our strategic advantages, organizational capabilities, and engagement intact. Brian, would you like to add to this?

Yeah. I think, as I mentioned in some of the commentary we provided early on in this, I think the stay-at-home policies that were implemented late March, very early April where we are seeing significant impacts and we didn’t have clarity on how that might evolve and thought it was prudent to get out in front of that. And as Jay highlighted, we had a goal of protecting employment and trying to find ways to mitigate what we were expecting in terms of some near-term impacts without damaging our underlying ability to advance our business strategy or serve customers. I think the intent was to cease those cuts when it made sense, I think we are very encouraged by the recent trends. It’s improving significantly day by day. And so I think we will keep an eye on this, but I think that was, that was the intent, the changes were implemented at a time where I think the depth of the impact from the social distancing policies was more significant.

Our next question will be from the line of Erin Wright with Credit Suisse. Go ahead.

Great. Thanks. Are you seeing any sort of changes in the competitive landscape at this point? Can you take advantage of any competitor disruption on either at the point of care side of the business or Reference Lab, given that you can withstand this sort of volatility to be a little bit more nimble in this environment? Thanks.

Thanks for the question, Erin. Yeah. We have always said that our markets have historically been very competitive. It’s no different now, even if it’s within the COVID-19 environment. They continue to be very competitive. We are very pleased with the inroads that we continue to make in terms of, if you take a look at the competitive catalyst placements globally, we were up 17% premium installed base year-over-year, 15%. We continue to expand Reference Lab testing. The point-of-care solutions like VetLab have held up relatively well in the COVID-19 environment. Now part of that is due to the fact that they support more sick patient testing with real-time results. If you take a look at the Reference Lab, for example, before the COVID-19 impact, we were at a solid middle teens in the U.S. from a growth standpoint, high single-digits internationally. So we did see some drop-off in volume in line with the visits and prioritizing case management, as Brian described it. But we have also seen even now, with the drop-off and the beginnings of a recovery that customers have a new appreciation, a far deeper appreciation for what we are bringing in terms of service levels, lab network, density, courier, logistics, all of those things. I think what they are seeing from some other participants in the marketplace is they don’t have that capability in that footprint to be able to provide that level of service.

Okay, great. And then can you remind us of the sustainability of pricing across your business in prior economic downturns? And can you also speak to how minimum purchase agreements associated with consumables are impacted from the COVID disruption as well? Thanks.

In the first quarter, we are seeing a modest price increase of between 2% and 3%. However, we are not making any forecasts about future pricing trends at this time. It's important to recognize that customers consider more than just price; they evaluate the overall value based on what they receive. We continuously assess the economics within that value framework. Regarding our programs, we have volume-based commercial initiatives, and in some instances, we are accommodating adjustments to our obligations because some programs reflect the current situation of reduced client traffic in testing volumes, and we want to support our customers through this.

And our next question will be from the line of Jon Block with Stifel. Go ahead.

Thanks guys. Good morning. Maybe for Jay or Brian, is there a way to think about how much sort of loss versus deferred revenue. In other words, your growth has been so consistent and durable every year around 10% to 12% organic. If the growth just to throw out a number is up low-single digits this year, when we think about 2021, can we sort of go back to that 10% to 12% off of that low single-digit number or is there a chance for, call it, a big acceleration mid-teens growth as we think about the deferred coming back? And I think that is just an important area that everyone is trying to get their arms around. I’m defaulting to lost revenue because an emergency would have occurred and I don’t think you do to wellness is in 1H ‘21, but maybe if you can go ahead and talk to that? That would be helpful.

Yeah. I think, as you point out, Jon, it’s a little difficult to estimate at the moment. I think our feeling is that there will be a level of pent-up demand here for care that will come back as people are able to access vet clinics. It’s likely there is a level of sick patient care that is just going to be lost in terms of the impacts at this time and it is just until we kind of work through this, and we are going to get back to what we think is going to be a rebound to a good place in terms of the industry’s health. It’s a little tough to project that out, which is why we are moving away from guidance at the moment. But I think the underlying fundamentals of the industry are very sound. We think that working through the dynamics with our customers will only reinforce these advantages that we have as a business, and I think we will be very well positioned to grow as we come out of this.

I want to share with you, Jon, some insights from veterinarians. Focusing on wellness, it's clear that if a patient is sick or needs surgery, those services are still available. In the first quarter, we reached a record in preventive care enrollments with 400, bringing the total to 4,200 so far. The key point about preventive care is that pet owners view it as essential and prioritize it for their pets. Veterinarians are telling us that not only do they view this as good medicine because it leads to better care, but it also benefits their practice's economics and enhances client engagement. From both a medical necessity and practice health perspective, there is a strong demand for these services. This aligns with Brian's comments about our optimism regarding pent-up demand and anticipating a V-shaped recovery. It will be an integral part of our recovery strategy, Recover Together, to emphasize this point. While there is still significant work to do regarding sick patient care alongside preventive services, we remain optimistic.

Okay. And Jay, maybe just a follow-up on that last point. The one thing that we are hearing about COVID-19 is just the change of workflow within the practice, curbside pickup sort of spacing out the visits more. At the end of the day, it is reducing the overall number of visits, just from a workflow perspective and I think it’s unclear how long this hangs around, right. How it plays out over time. So you talk about this V-shaped recovery, but do you have any concerns that this altered workflow has a lasting impact sort of which results in a more protracted return to normal for the industry? Thanks.

I have a few observations. In the first couple of weeks, veterinary practices struggled to adapt their workflows. This was partly due to a decrease in visits and partly because they had to lengthen appointment blocks, which made things more challenging. We collaborated with customers through our field service team to help them design new workflows for curbside drop-off and pickup, remote check-in, and contactless payment processes. They have improved significantly, as expected, with time leading to optimized processes. Different states and regions are at various stages of recovery, initially handling everything from the parking lot. I believe we will see some relaxation of these restrictions over time. Connecting your two questions, I want to mention that practices have seen significant competition from e-tailers, leading to many food and medicine sales shifting online. Much of this business may not return to previous levels, which will increase the importance of getting patients back into practices for checkups and diagnostics. We will monitor how this evolves, but overall, the trends are looking positive.

We have a question in queue from the line of Ryan Daniels with William Blair. Go ahead.

Yeah, guys. Thanks for taking the questions. Jay, can you talk a little bit more about Recover Together? It sounds like you have developed a specific blueprint for kind of the bounce back. So I’m curious what that involves and how your marketing that.

Yeah. I mean, it really comes out with the fact that, even within this COVID-19 environment, we are still highly engaged with our customers. Our customer-facing folks are visiting customers 75%, just take the U.S. for example is virtual, but 25% when requested were present and fully decked out in safety care. So there is a high level of engagement. We are building pipeline. We are working with our customers in terms of developing strategies that as we recover, they rebuild client traffic. We saw coming out of the great recession in 2009 that a lot of really good clients or pet owners returned almost immediately. Where the veterinarians I think needed some help and assistance is for those relatively new clients to help build the muscle memory of semi-annual or annual visits. So we are looking at programs that we have for example our Preventive Care program is perfect for that. And even the sick patient visits allowed are advised, there are still some things that people are likely pet owners and likely deferring. So we are looking at all of our programs to be able to support that. Just one word on the IDEXX 360, because it’s really tailor-made for this type of environment. If you think about IDEXX 360, you are able to get capital purchases with zero money down. So if you are veterinary practice if you are in this constrained environment from an economic standpoint, you can still purchase instruments and you pay on a monthly basis and you are able to match invoicing to the customer with testing volumes. So in some ways it’s really tailor-made to test for this type of environment. So we are looking at all of those things in terms of how to support customers.

Okay. That’s very helpful. Thank you. And then a little bit more color on OPTI Medical. I know that doesn’t get a lot of airtime, an acquisition you did to benefit the companion animal business. But what’s the potential for that if you get FDA approval and kind of how will that process go? I assume you will have a distribution partner for that in the human market, any color there? Thanks guys.

We have developed and validated a human real-time PCR test for COVID-19. In response to your question, we utilized the capabilities of OPTI, our human health business, from a regulatory and channel perspective, alongside our experience in developing and manufacturing livestock infectious disease kits. This is a PCR test that demonstrates high effectiveness in terms of sensitivity and specificity. Typically, results are available in under four hours, making it relatively quick. OPTI is currently in the process of using the FDA’s Emergency Use Authorization process, and we are awaiting approval. We have also applied for CE Mark approval in the European Union. We are enhancing our manufacturing capabilities in our Livestock, Poultry, and Dairy business and are aiming for initial distribution to our existing IDEXX customers. We are not relying on external channels, and this includes livestock laboratories, public health laboratories, and state CDC labs.

Our next question, we will go to Nathan Rich with Goldman Sachs. Go ahead please.

Hi. Good morning. Thanks for the question. I guess to start, I think, Jay, you mentioned, vet services are tended to be pretty resilient during past downturns and obviously consumers are going to be facing kind of uncertain economic conditions coming out of this. I guess I’d be curious just, when you look at wellness visits in recent weeks, I mean, has there been any change in metrics like the percentage of those visits that include blood work, the number of test orders that might provide an indication of the consumer’s ability to spend on diagnostics for their pets?

I will address your question on a couple of levels, considering the recessionary environment and how resilient our business has been, which is certainly the case. Looking back at the Great Recession in 2009, we performed remarkably well with a 5% growth coming out of that low point. Fast forward ten years, and I believe we are in an even stronger position to succeed in a V-shaped recovery. Our business is well diversified across various geographies and sectors such as CAG, Water, livestock, poultry, and dairy, along with different modalities and numerous shapes. I would like to highlight a couple of aspects, including our commercial organization. A decade ago, we primarily relied on distributors, whereas now we have more direct representation, reducing our dependence on others. Additionally, our portfolio has expanded significantly to include not only sick care but wellness components as well. The importance of diagnostics is now better understood and recognized for its critical role in ensuring both quality medical care and overall practice health. Regarding diagnostics over the past few weeks, we currently lack visibility on that data, but we will keep monitoring it weekly concerning lab accessions and smart service testing. It is still too early to provide a specific answer to your question.

I want to emphasize that as we analyze the data on a daily basis, it's very encouraging to see how quickly things are recovering. We believe this reaffirms the strong willingness we've observed among pet owners to invest in essential care for their pets, who are now considered family members. This commitment seems even stronger now compared to over a decade ago during the last major recession. Early signs are promising, and we will keep a close eye on these areas moving forward. Great. Thanks. Just a quick follow-up, as you have seen restrictions start to ease in some areas, have you also seen kind of rep visits pick back up, I’m just curious to know if there could maybe be more prolonged impact there? Is that’s kind of one of limit the number of sales reps that they see in the clinic, just due to the concerns around COVID?

I’m sorry, I missed that part where you said the number of what visits pick back.

I'm sorry. Have your sales representatives been able to start visiting customers in areas where restrictions have eased, and could that have a more lasting effect on their ability to engage with clients?

Yeah. Okay. I got it. Absolutely. The way we conduct visits today is when customers ask us to be present or that differs than a lot of other companies out there that have essentially 100% virtual visit policy. So if you take a look at April, for example, 25% of the visits of the field organization was actually physically visiting the practice. Now, if you break that down by states and regions, it did differ based on how strict the social distancing procedures were in the practice. What we saw in places like Texas and the South relatively more visits, relatively higher visit levels in terms of clients and more testing. Impacted - higher impacted regions like the Northeast and the Great Lakes, for example, a bit lower. So, very much in line and proportional to what the local guidelines are per se per region.

We have a question in queue from the line of David Westenberg. Just one moment please while we open his line.

All right. Thank you for taking the questions. So I’m just a layer on some of the questions that have already been asked. Can you talk about your balance sheet right now, some of the rationale between taking on the additional debt. Is that at all sense, can we expect at the practice level, maybe there are some liquidity needs, and right now it’s your opportunity to help those practices that need to preserve cash? And then, just related to that, do you think that they are going to be more likely to avoid the cash flow and sign the contract or do you think there might actually be some hesitancy on that contract? And then as a follow-up on the near term, can you quantify the pent-up demand? I know VCA used to say in their practice, they have an 80% recovery rate in a snowstorm kind of environment of those appointments. Is that a good way to think about it in terms of when social distancing ends and I will take these questions offline? Thank you.

Thank you, David. Regarding your question about our balance sheet, some of the initiatives we outlined were already in progress before the pandemic significantly affected our business. We were working on securing terminal financing at favorable rates and were able to execute that successfully. Our revolver was due for renegotiation this year, so we proactively advanced that process, extending and increasing it. We feel we are in a strong position and have actually improved our position. You’ve made an important point; this allows us to continue to be very supportive of our customers. We are assisting independent practices in the U.S. and Europe with payment term flexibility in the short term, doing our best to help. As Jay noted, our programs are well designed to support those with immediate concerns about cash flow management, enabling them to keep advancing their businesses. We will keep focusing on this and find effective ways to help practices as we work together towards returning to normal over time.

I mean, I would just also again reemphasize the IDEXX 360 program is ideal in many respects for new customer acquisition and its environment. No cash outlays matching customer invoices with the use of consumables. And the other thing, David, is we are able to calibrate future commitment expectations for customers in terms of how we use this. So, I think we all recognize that this is a unique environment and we can highly configure these type of volume commitment programs for that environment.

And then if I could just get on that the recovery rate, if there’s any way to quantify like if VCA’s 80% recovery on weather-related thing that used to give five years ago when they were public, but…

We don’t have specific benchmarks for this situation, and I’m unsure if using a snowstorm as an analogy is appropriate right now. It varies significantly from region to region, but overall, we are encouraged by the rapid increase in demand as the policies become less restrictive, and we are optimistic about the future developments.

We will go next to the line of Andrew Cooper with Raymond James. Go ahead please.

Hey, everybody. Thanks for the questions. A lot is uncovered. So I will maybe just ask one kind of attacking something a little bit differently. But as we think about the transition to virtual visits and obviously you are still doing a number of in-person, but when we think about installs, you have done a lot of second instruments and things like that as a portion of your growth. When we think about demand for that, obviously, it’s a little bit different than sort of a net new competitive placement, but how do we think about exiting when clinics aren’t necessarily seeing the same volumes that they were? Does that delay that need or potentially have clinics that are well capitalized sitting there saying, hey, we can get an installing without really disrupting as busy of a day where we are kind of working at full capacity as it is. Any comment there just kind of on the pace of instrument installations would be great as you come out of this.

There are several questions in that. Let me address your point about the placement of second catalysts at practices. These are typically installed at higher volume customers, so it's not a matter of having a second catalyst just sitting unused. The demand for a second catalyst often arises when a practice is expanding, leading to increased client visits. This system is highly modular, which makes it a volume-driven decision for customers. We believe that, from a recovery perspective as well as in terms of long-term trends, the utilization of diagnostics will remain strong for both sick patients and preventive care. Our product roadmap and the various assays we are introducing will continue to drive usage and utilization, although it may be somewhat reduced currently due to the prevailing environment. We believe that all the dynamics and value drivers remain in place, so we don't anticipate any changes in that regard through the recovery period.

We have time for one more question.

I will stop there if anybody else is in the queue. Thank you.

That will come from the line of Michael Ryskin with Bank of America. Go ahead please.

Hey, guys. Thanks. I think I dropped off the initial one. Thanks for the follow-up. Just real quick, I want to go back to some of my concern sort of longer term about the vet dynamic. As we think through this impact sort of what’s forefront of my mind is that, that’s going to be economically challenged here in potentially for an extended period of time. Both from economic recession and potentially some tail risk here in terms of volumes. So how do you think about vets being a little bit more price sensitive around their offerings and we know that IDEXX is definitely the premium brand in the space in terms of pricing compared to Heska and Abaxis and the cheaper alternatives. Are you concerned that would be while diagnostics utilization overall and visits made holding pretty well due to the economic challenges and some of the pressures on them, they may trade down to some of the cheaper offerings?

So here’s how we think about it, Mike. Customers have always been focused on the economics of the solution, which hasn't changed. Price is one aspect, but the value we provide is another significant factor. We constantly test to ensure that the value and economics align. Our goal is to tailor our programs to meet the needs of our customers based on their specific environments and circumstances, allowing them to acquire the best tools for delivering optimal care. From this perspective, our solutions remain unchanged in terms of what customers view as the best fit for their needs. We offer programs that help them access the products and services they desire in a manner that suits their financial constraints, ensuring a match between the invoices they issue to their clients and what they owe us. We are confident in our ability to meet their timelines while being sensitive to the economic landscape. And with that, I want to thank everybody for calling in. I know we have some employees who are also on the call and I’d like to express my gratitude for their extraordinary performance there in these unsettling times. We run the company in a way that both delivers the day and takes a long-term view designed to maintain and grow the strategic advantages of our business. I couldn’t be more proud of the IDEXX team and the purpose, which animates our work. And so with that, we will conclude the call. Thank you.

Ladies and gentlemen, that will conclude your conference call for today. Thank you for your participation and for using AT&T Event Teleconferencing. You may now disconnect.